Stock Analysis

Top Dividend Stocks To Consider In December 2024

Published

As global markets navigate a complex landscape marked by rate cuts from the ECB and SNB, and anticipation of a Fed cut, investors are closely watching shifts in major indices. Despite most indexes ending lower, the Nasdaq Composite reached new heights, highlighting the ongoing outperformance of growth stocks over value. In this environment of fluctuating economic indicators and market volatility, dividend stocks can offer stability through regular income streams, making them an attractive consideration for those seeking to balance risk with potential returns.

Top 10 Dividend Stocks

NameDividend YieldDividend Rating
Tsubakimoto Chain (TSE:6371)4.27%★★★★★★
Wuliangye YibinLtd (SZSE:000858)3.22%★★★★★★
CAC Holdings (TSE:4725)4.76%★★★★★★
Yamato Kogyo (TSE:5444)4.11%★★★★★★
Guangxi LiuYao Group (SHSE:603368)3.23%★★★★★★
Padma Oil (DSE:PADMAOIL)7.43%★★★★★★
Nihon Parkerizing (TSE:4095)3.97%★★★★★★
China South Publishing & Media Group (SHSE:601098)3.80%★★★★★★
HUAYU Automotive Systems (SHSE:600741)4.19%★★★★★★
E J Holdings (TSE:2153)3.88%★★★★★★

Click here to see the full list of 1868 stocks from our Top Dividend Stocks screener.

Below we spotlight a couple of our favorites from our exclusive screener.

Médica Sur. de (BMV:MEDICA B)

Simply Wall St Dividend Rating: ★★★★☆☆

Overview: Médica Sur, S.A.B. de C.V. operates as a healthcare hospital in Mexico with a market cap of MX$3.60 billion.

Operations: Médica Sur, S.A.B. de C.V. generates revenue from its operations as a healthcare hospital in Mexico.

Dividend Yield: 4.5%

Médica Sur's dividend payments are well-covered by earnings and cash flows, with payout ratios of 42.8% and 52.1%, respectively, but have been volatile over the past decade. Despite a low dividend yield of 4.45% compared to top-tier MX payers, dividends have grown over ten years. Recent earnings show increased sales but declining net income and EPS year-over-year, impacting their financial stability for consistent dividends in the future.

BMV:MEDICA B Dividend History as at Dec 2024

Exacompta Clairefontaine (ENXTPA:ALEXA)

Simply Wall St Dividend Rating: ★★★★★☆

Overview: Exacompta Clairefontaine S.A. is involved in the production, finishing, and formatting of papers across France, Europe, and internationally with a market cap of €166.33 million.

Operations: Exacompta Clairefontaine S.A. generates revenue from its Paper segment, amounting to €354.56 million, and its Conversion segment, which totals €597.58 million.

Dividend Yield: 4.6%

Exacompta Clairefontaine's dividends have been stable and reliable over the past decade, with consistent growth. The dividend payments are well-covered by earnings and cash flows, indicated by a payout ratio of 35.4% and a cash payout ratio of 10.7%. However, its dividend yield of 4.56% is below the top tier in France. Despite trading significantly below estimated fair value, recent profit margins have decreased from last year’s levels.

ENXTPA:ALEXA Dividend History as at Dec 2024

Kangwon Land (KOSE:A035250)

Simply Wall St Dividend Rating: ★★★★★☆

Overview: Kangwon Land, Inc. operates in the casino, tourist hotel, and ski resorts sectors in South Korea with a market cap of ₩3.41 trillion.

Operations: Kangwon Land, Inc. generates revenue from its Casinos & Resorts segment, amounting to ₩1.41 trillion.

Dividend Yield: 5.5%

Kangwon Land's dividend yield of 5.46% ranks in the top 25% of the Korean market, supported by a payout ratio of 45.1%, indicating dividends are well-covered by earnings. However, its cash payout ratio is higher at 80.4%. Recent buybacks totaling KRW 40 billion could enhance shareholder value, yet dividend stability remains a concern due to past volatility and unreliability over ten years. Despite trading below fair value, earnings growth faces future challenges.

KOSE:A035250 Dividend History as at Dec 2024

Make It Happen

Looking For Alternative Opportunities?

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Valuation is complex, but we're here to simplify it.

Discover if Exacompta Clairefontaine might be undervalued or overvalued with our detailed analysis, featuring fair value estimates, potential risks, dividends, insider trades, and its financial condition.

Access Free Analysis

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com